Nurix Therapeutics, INC 8-K filings

Nurix Therapeutics announced a significant global collaboration with Roche for bexobrutideg, potentially worth up to $2.3 billion, alongside its second-quarter financial results which showed a net loss but a strong cash position bolstered by the expected upfront payment.

Nurix Therapeutics announced updated clinical data for bexobrutideg, a BTK degrader, showing high response rates and durable efficacy in chronic lymphocytic leukemia patients.

Nurix Therapeutics and Roche have entered into a global collaboration to co-develop and co-commercialize bexobrutideg, a BTK degrader, with potential total payments up to $2.3 billion.

Nurix Therapeutics stockholders re-elected three directors and ratified the appointment of its independent auditor.

Nurix Therapeutics announced its first quarter 2026 financial results, highlighting progress in its bexobrutinib program and a well-capitalized balance sheet.

Nurix Therapeutics, Inc. amended its equity distribution agreement to increase its at-the-market offering capacity to $413.65 million, providing additional funding flexibility.

Nurix Therapeutics announced its financial results for the fiscal quarter and year ended November 30, 2025, highlighting significant progress in its clinical programs, including the initiation of a pivotal study for bexobrutideg in CLL and a strengthened balance sheet.

Nurix Therapeutics presented its 2025 performance and 2026 strategic objectives at the J.P. Morgan Healthcare Conference, focusing on advancing its targeted protein degradation pipeline.

Nurix Therapeutics announced compelling new clinical data for its BTK degrader bexobrutideg in relapsed or refractory CLL, SLL, and WM, demonstrating durable responses and a favorable safety profile.

Nurix Therapeutics strengthens its board with the appointment of Dr. Roger Dansey, a seasoned biopharmaceutical leader with extensive experience in oncology drug development and commercialization.

Nurix Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 24.5 million shares of common stock, expecting to raise $234.3 million in net proceeds for clinical development and R&D.

Nurix Therapeutics announced the initiation of its pivotal Phase 2 DAYBreak clinical trial for bexobrutideg in relapsed or refractory chronic lymphocytic leukemia, alongside positive updates for NX-1607 and other pipeline programs.

Nurix Therapeutics announced its third-quarter 2025 financial results, reporting an increased net loss while advancing pivotal trials for bexobrutideg and progressing strategic collaborations.

Nurix Therapeutics, Inc. presented updated clinical development plans and positive Phase 1 data for its investigational BTK degrader, bexobrutideg, in B-cell malignancies.

Nurix Therapeutics announced the resignation of Dr. Lori A. Kunkel from its Board and committee roles, with Dr. Roy D. Baynes appointed as the new chair of the Clinical and Commercialization Committee.

Nurix Therapeutics announced robust second-quarter fiscal year 2025 financial results, driven by significant collaboration milestones and positive clinical data for its lead drug candidates, positioning the company for pivotal trials and continued pipeline expansion.

Nurix Therapeutics announced compelling updated Phase 1 clinical data for its investigational BTK degrader, bexobrutideg (NX-5948), demonstrating high objective response rates and a favorable safety profile in heavily pretreated patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM), with pivotal trials slated for 2025.

Nurix Therapeutics successfully held its 2025 Annual Meeting of Stockholders, where shareholders elected directors, ratified the appointment of PricewaterhouseCoopers LLP, and approved executive compensation.

Nurix Therapeutics announces its Q1 2025 financial results, highlighted by collaboration milestones, regulatory achievements, and leadership team enhancements.

Nurix Therapeutics appoints Roy D. Baynes, a drug development expert, to its board of directors, effective immediately.

Nurix Therapeutics announces positive clinical data for NX-5948, provides updates on other programs, and reports its fiscal year 2024 financial results, highlighting a strong cash position.

Nurix Therapeutics announces its 2025 goals, including initiating pivotal trials for NX-5948 and expanding its pipeline, while reporting a strong cash position of $609.6 million as of November 30, 2024.

Nurix Therapeutics presented promising clinical data for its BTK degrader NX-5948, showing high response rates and tolerability in patients with relapsed or refractory chronic lymphocytic leukemia.

Nurix Therapeutics has entered into an agreement to sell up to $300 million of its common stock through an at-the-market offering.

Nurix Therapeutics has appointed Anil Kapur, a seasoned pharmaceutical executive, to its board of directors to leverage his commercialization expertise as the company advances its pipeline.

Nurix Therapeutics announced its third quarter fiscal 2024 financial results, highlighted by the expansion of clinical trials for NX-5948 and a strong cash position.

Nurix Therapeutics presented updates on its clinical trials, including promising results for NX-5948 in B-cell malignancies and plans for pivotal studies in 2025.

Nurix Therapeutics reported positive clinical data for NX-5948, strengthened its leadership team, and ended the quarter with $452.5 million in cash and marketable securities.

Nurix Therapeutics reported a 69.2% objective response rate in a Phase 1 clinical trial of NX-5948 for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with BTK inhibitor resistance.

Nurix Therapeutics successfully held its 2024 Annual Meeting, electing two Class I directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.